[Dyspepsia, Ulcer Disease – Helicobacter pylori, Gastroesophageal Reflux Disease].

Related Articles

[Dyspepsia, Ulcer Disease – Helicobacter pylori, Gastroesophageal Reflux Disease].

Praxis (Bern 1994). 2016 Jun 8;105(12):693-7

Authors: Wirth HP

Abstract
Prevalence of H. pylori (HP) is declining, whereas reflux disease and the proportion of non-steroidal antiinflammatory drugs (NSAR) to HP-induced ulcers increase. Eradication heals HP-ulcer disease, interrupts cancerous progression and can improve dyspeptic symptoms. NSAR-ulcers heal under proton pump inhibitor (PPI) therapy but tend to recur after reexposition. Anticoagulants and antiplatlet agents increase the risk additionally. PPI reduces NSAR-ulcer recurrence. Reflux patients with severe inflammation and complications often need long-term therapy. Barrett's esophagus patients are at risk of esophageal adenocarcinoma.

PMID: 27269775 [PubMed - in process]

from #ENT via xlomafota13 on Inoreader http://ift.tt/2c7PzFL
via IFTTT